Literature DB >> 27956622

β2-Adrenergic receptor-dependent chemokine receptor 2 expression regulates leukocyte recruitment to the heart following acute injury.

Laurel A Grisanti1, Christopher J Traynham1, Ashley A Repas1, Erhe Gao1, Walter J Koch1, Douglas G Tilley2.   

Abstract

Following cardiac injury, early immune cell responses are essential for initiating cardiac remodeling and tissue repair. We previously demonstrated the importance of β2-adrenergic receptors (β2ARs) in the regulation of immune cell localization following acute cardiac injury, with deficient leukocyte infiltration into the damaged heart. The purpose of this study was to investigate the mechanism by which immune cell-expressed β2ARs regulate leukocyte recruitment to the heart following acute cardiac injury. Chemokine receptor 2 (CCR2) expression and responsiveness to C-C motif chemokine ligand 2 (CCL2)-mediated migration were abolished in β2AR knockout (KO) bone marrow (BM), both of which were rescued by β2AR reexpression. Chimeric mice lacking immune cell-specific CCR2 expression, as well as wild-type mice administered a CCR2 antagonist, recapitulated the loss of monocyte/macrophage and neutrophil recruitment to the heart following myocardial infarction (MI) observed in mice with immune cell-specific β2AR deletion. Converse to β2AR ablation, β2AR stimulation increased CCR2 expression and migratory responsiveness to CCL2 in BM. Mechanistically, G protein-dependent β2AR signaling was dispensable for these effects, whereas β-arrestin2-biased β2AR signaling was required for the regulation of CCR2 expression. Additionally, activator protein 1 (AP-1) was shown to be essential in mediating CCR2 expression in response to β2AR stimulation in both murine BM and human monocytes. Finally, reconstitution of β2ARKO BM with rescued expression of a β-arrestin-biased β2AR in vivo restored BM CCR2 expression as well as cardiac leukocyte infiltration following MI. These results demonstrate the critical role of β-arrestin2/AP-1-dependent β2AR signaling in the regulation of CCR2 expression and recruitment of leukocytes to the heart following injury.

Entities:  

Keywords:  C-chemokine receptor 2; cardiac injury; leukocyte; β-arrestin; β2-adrenergic receptor

Mesh:

Substances:

Year:  2016        PMID: 27956622      PMCID: PMC5206565          DOI: 10.1073/pnas.1611023114

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  Association of beta-arrestin and TRAF6 negatively regulates Toll-like receptor-interleukin 1 receptor signaling.

Authors:  Yaya Wang; Yawei Tang; Lin Teng; Yalan Wu; Xiaohui Zhao; Gang Pei
Journal:  Nat Immunol       Date:  2005-12-25       Impact factor: 25.606

2.  Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow.

Authors:  Yoshio Katayama; Michela Battista; Wei-Ming Kao; Andrés Hidalgo; Anna J Peired; Steven A Thomas; Paul S Frenette
Journal:  Cell       Date:  2006-01-27       Impact factor: 41.582

3.  Activation of the nuclear factor of activated T-cells (NFAT) mediates upregulation of CCR2 chemokine receptors in dorsal root ganglion (DRG) neurons: a possible mechanism for activity-dependent transcription in DRG neurons in association with neuropathic pain.

Authors:  Hosung Jung; Richard J Miller
Journal:  Mol Cell Neurosci       Date:  2007-09-14       Impact factor: 4.314

Review 4.  Autonomic innervation and regulation of the immune system (1987-2007).

Authors:  Dwight M Nance; Virginia M Sanders
Journal:  Brain Behav Immun       Date:  2007-04-27       Impact factor: 7.217

5.  beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor.

Authors:  Sudha K Shenoy; Matthew T Drake; Christopher D Nelson; Daniel A Houtz; Kunhong Xiao; Srinivasan Madabushi; Eric Reiter; Richard T Premont; Olivier Lichtarge; Robert J Lefkowitz
Journal:  J Biol Chem       Date:  2005-11-09       Impact factor: 5.157

6.  Activation of mitogen-activated protein kinases in the non-ischemic myocardium of an acute myocardial infarction in rats.

Authors:  K Yoshida; M Yoshiyama; T Omura; Y Nakamura; S Kim; K Takeuchi; H Iwao; J Yoshikawa
Journal:  Jpn Circ J       Date:  2001-09

Review 7.  Targeting inflammation by modulating the Jun/AP-1 pathway.

Authors:  Helia B Schonthaler; Juan Guinea-Viniegra; Erwin F Wagner
Journal:  Ann Rheum Dis       Date:  2011-03       Impact factor: 19.103

8.  c-Jun DNAzymes inhibit myocardial inflammation, ROS generation, infarct size, and improve cardiac function after ischemia-reperfusion injury.

Authors:  Xiao Luo; Hong Cai; Jun Ni; Ravinay Bhindi; Harry C Lowe; Colin N Chesterman; Levon M Khachigian
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-07-10       Impact factor: 8.311

9.  MCP-1/CCL2 protects cardiac myocytes from hypoxia-induced apoptosis by a G(alphai)-independent pathway.

Authors:  Sima T Tarzami; Tina M Calderon; Arnel Deguzman; Lillie Lopez; Richard N Kitsis; Joan W Berman
Journal:  Biochem Biophys Res Commun       Date:  2005-10-07       Impact factor: 3.575

10.  Differential signaling mechanisms regulate expression of CC chemokine receptor-2 during monocyte maturation.

Authors:  Roderick J Phillips; Marin Lutz; Brett Premack
Journal:  J Inflamm (Lond)       Date:  2005-10-31       Impact factor: 4.981

View more
  20 in total

1.  β-arrestin-biased agonism of β-adrenergic receptor regulates Dicer-mediated microRNA maturation to promote cardioprotective signaling.

Authors:  Jian-Peng Teoh; Ahmed S Bayoumi; Tatsuya Aonuma; Yanyan Xu; John A Johnson; Huabo Su; Neal L Weintraub; Yaoliang Tang; Il-Man Kim
Journal:  J Mol Cell Cardiol       Date:  2018-04-06       Impact factor: 5.000

2.  Restricting mitochondrial GRK2 post-ischemia confers cardioprotection by reducing myocyte death and maintaining glucose oxidation.

Authors:  Priscila Y Sato; J Kurt Chuprun; Laurel A Grisanti; Meryl C Woodall; Brett R Brown; Rajika Roy; Christopher J Traynham; Jessica Ibetti; Anna M Lucchese; Ancai Yuan; Konstantinos Drosatos; Doug G Tilley; Erhe Gao; Walter J Koch
Journal:  Sci Signal       Date:  2018-12-11       Impact factor: 8.192

3.  Prior β-blocker treatment decreases leukocyte responsiveness to injury.

Authors:  Laurel A Grisanti; Claudio de Lucia; Toby P Thomas; Aron Stark; John T Strony; Valerie D Myers; Remus Beretta; Daohai Yu; Celestino Sardu; Raffaele Marfella; Erhe Gao; Steven R Houser; Walter J Koch; Eman A Hamad; Douglas G Tilley
Journal:  JCI Insight       Date:  2019-03-28

4.  Validation of diagnostic criteria and histopathological characterization of cardiac rupture in the mouse model of nonreperfused myocardial infarction.

Authors:  Anis Hanna; Arti V Shinde; Nikolaos G Frangogiannis
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-09-04       Impact factor: 4.733

5.  Recent Advances in GPCR-Regulated Leukocyte Responses during Acute Cardiac Injury.

Authors:  Tapas K Nayak; Douglas G Tilley
Journal:  Curr Opin Physiol       Date:  2020-09-15

Review 6.  Anti-inflammatory therapies in myocardial infarction: failures, hopes and challenges.

Authors:  Shuaibo Huang; Nikolaos G Frangogiannis
Journal:  Br J Pharmacol       Date:  2018-03-04       Impact factor: 8.739

7.  Cell biological mechanisms in regulation of the post-infarction inflammatory response.

Authors:  Nikolaos G Frangogiannis
Journal:  Curr Opin Physiol       Date:  2017-12-13

8.  Stress-induced Norepinephrine Downregulates CCL2 in Macrophages to Suppress Tumor Growth in a Model of Malignant Melanoma.

Authors:  Kayla J Steinberger; Michael T Bailey; Amy C Gross; Laura A Sumner; Jeffrey L Voorhees; Nisha Crouser; Jennifer M Curry; Yijie Wang; A Courtney DeVries; Clay B Marsh; Ronald Glaser; Eric V Yang; Timothy D Eubank
Journal:  Cancer Prev Res (Phila)       Date:  2020-06-09

Review 9.  Chemokines in Myocardial Infarction.

Authors:  Bijun Chen; Nikolaos G Frangogiannis
Journal:  J Cardiovasc Transl Res       Date:  2020-05-15       Impact factor: 4.132

Review 10.  Obesity: a neuroimmunometabolic perspective.

Authors:  Chelsea M Larabee; Oliver C Neely; Ana I Domingos
Journal:  Nat Rev Endocrinol       Date:  2019-11-27       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.